NeoTract Announces Aetna US Healthcare and Coventry Health Care Positive Coverage Decision Regarding UroLift® Implant Procedure for Men with Enlarged Prostate
PR Newswire Association LLC |
"This positive coverage decision from a leading insurer is a welcome validation of the clinical benefits and cost effectiveness of the UroLift® System in treating men with BPH," said
About BPH
Benign prostatic hyperplasia (BPH), also known as enlarged prostate, is a medical condition in which the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. The condition is common, affecting approximately 37 million men in
Medication is often the first line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts or ablates prostate tissue to open the blocked urethra. While current surgical options, such as the 'gold standard' surgery, TURP, can be very effective in relieving symptoms, it can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).
About UroLift
The UroLift System permanent implants, delivered during a minimally-invasive procedure, effectively treat BPH by acting like window curtain tie-backs to hold the lobes of an enlarged prostate open. Patients recover from the procedure quickly, and return to their normal routines with minimal downtime. Learn more at www.UroLift.com.
About NeoTract
SOURCE
Wordcount: | 498 |
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News